Ετικέτες

Τρίτη 3 Νοεμβρίου 2020

Adenocarcinoma of the urinary bladder with inferior vena cava thrombus

alkiviadis.1961 shared this article with you from Inoreader

Message:


Harkirat Singh Talwar and Vikas Kumar Panwar
Author affiliations
Urology, All India Institute of Medical Sciences—Rishikesh, Rishikesh, India
Correspondence to Dr Vikas Kumar Panwar; vikaspanwar.dr@gmail.com
http://dx.doi.org/10.1136/bcr-2020-237772

Statistics from Altmetric.com
Request Permissions
Description
Adenocarcinoma of the bladder is an unusual malignancy arising most commonly from the dome and posterior wall of the bladder. It has a male predominance seen during the sixth and seventh decade.1 It arises from the urothelium although has a pure glandular histology.2 Haematuria is the most common presenting symptom and various cystoscopic morphologies exist like solid, papillary, sessile or ulcerated. Notable risk factors for adenocarcinoma include schistosomiasis, chronic irritation, cystocoele and exstrophy bladder. Adenocarcinoma of the bladder may be primary in origin or may be secondary to involvement by adjacent organs. Urachal adenocarcinoma although a separate entity is frequently grouped with bladder adenocarcinoma. No case has been ever reported in the literature of a bladder carcinoma with inferior vena cava (IVC) thrombus. This is a first case of its kind to be reported with tumour extending through the iliac veins into the IVC.

A 60-year-old man presented with haematuria and history of transurethral resection of bladder mass done elsewhere. General and physical examination revealed no positive findings and he had a poor performance status. Histopathology was suggestive of adenocarcinoma of the urinary bladder with tumour infiltrating the deep muscle. Contrast enhanced CT scan revealed 7.2×6.5 cm mass arising from the dome and the right posterolateral wall of the urinary bladder and extending into right ureter for a length of 3.5 cm causing gross hydroureteronephrosis (figure 1). The mass was seen extending into the small bowel mesentery and the mesorectal fascia and seminal vesicles. An enhancing tumour thrombus was also seen for a length of 5.2 cm in the distal IVC extending into bilateral common iliac veins and the right internal and external iliac veins. Metastatic work up revealed extensive lesions in the lungs and the skeleton (figure 2). Creatinine clearance of the patient improved to 70 mL/m in post insertion of the nephrostomy tube. The patient was started on low-molecular weight heparin and also received palliative chemotherapy. The patient succumbed to illness 3 months after presentation.


Figure 1
Download figure
Open in new tab
Download powerpoint
Figure 1
Coronal sections showing the bladder mass and the inferior vena cava thrombus (A) and the upstream right hydroureteronephrosis as a result of the bladder mass and right ureteric extension (B).

Figure 2
Download figure
Open in new tab
Download powerpoint
Figure 2
Axial section of the thorax revealing multiple parenchymal pulmonary metastatic deposits.

Prevention of pulmonary embolism is of utmost priority in such patients with anticoagulation and IVC filter being the mainstay.3 Although low-molecular weight heparin is preferred with total/near total tumour thrombus or those with a bland thrombus, IVC filter may be required in patients when anticoagulation fails or is contraindicated. Treatment of the malignancy according to standard guidelines is mandated thereafter.4 Radical cystectomy and pelvic lymph node dissection remains the standard of care for localised disease as chemotherapy has not shown to improve outcomes in adenocarcinoma of bladder. Platinum-based chemotherapy regimens used against urothelial carcinoma are not effective against adenocarcinoma. Majority of patients have muscle invasive disease at presentation and prognosis remains poor with adenocarcinoma of urinary bladder having a poorer stage by stage survival outcome as compared with its urothelial counterpart.

Learning points
Primary adenocarcinomas of the urinary bladder are rare tumours and are usually detected at an advanced stage and thus have poor prognosis.

Bladder cancers can present with inferior vena cava (IVC) thrombus with a possible route being through the internal and common iliac veins. This is the first case to be reported of a bladder carcinoma with IVC thrombus.

Anticoagulation and prevention of pulmonary embolism remains the top priority in such cases followed by stage-based management following standard guidelines.

References
↵Dadhania V, Czerniak B, Guo CC. Adenocarcinoma of the urinary bladder. Am J Clin Exp Urol 2015;3:51–63.pmid:http://www.ncbi.nlm.nih.gov/pubmed/26309895PubMedGoogle Scholar
↵Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67:2165–72.doi:10.1002/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-Mpmid:http://www.ncbi.nlm.nih.gov/pubmed/1706216CrossRefPubMedWeb of ScienceGoogle Scholar
↵Pandhi MB, Desai KR, Ryu RK, et al. The role of inferior vena cava filters in cancer patients. Semin Intervent Radiol 2016;33:071–4.doi:10.1055/s-0036-1581090pmid:http://www.ncbi.nlm.nih.gov/pubmed/27247473PubMedGoogle Scholar
↵Black PC, Brown GA, Dinney CPN. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009;27:3–7.doi:10.1016/j.urolonc.2007.07.010pmid:http://www.ncbi.nlm.nih.gov/pubmed/18367107PubMedGoogle Scholar

BMJ_CaseReports_logo_Twitter_Card.png

View on the web

Extended pulsed radiofrequency as a part of multimodal pain management in a refractory case of Bernhardt-Roth syndrome

alkiviadis.1961 shared this article with you from Inoreader

BMJ_CaseReports_logo_Twitter_Card.png

Bernhardt-Roth syndrome (BRS) is a neurological condition characterised by pain, burning or numbness in anterolateral thigh due to entrapment of the lateral femoral cutaneous nerve (LFCN). The possible aetiologies can be mechanical, iatrogenic, neuropathic or idiopathic. After consent for possible publication, we are discussing a case of pain management in a 38-year-old patient with BRS secondary to diabetes. The coherent history, uncontrolled glycaemic status and reduced nerve conduction velocity for LFCN helped reach the diagnosis. Initial treatment with pharmacotherapy, steroid LFCN block and conventional pulsed radiofrequency (PRF) provided moderate temporary pain relief. Extended PRF over 8 min provided significant analgesia without any complications. Physical therapy, adequate glycaemic control and extended PRF provided complete pain relief and improved function over 6 months of follow-up duration. Hence, a cautious multifaceted approach targeting the basic aetiology with extended PRF helped achieve significant analgesia in our refractory case of BRS.

View on the web

Haemolymphatic cancer among children

alkiviadis.1961 shared this article with you from Inoreader

bmjopen-default-cover.png

Objectives

To explore the time trend and geographical distribution of childhood leukaemia incidence over the territory of the Italian region of Sardinia.

Setting

All hospitals departments, diagnostic centres and social security agencies in Sardinia were regularly screened in 1974–2003 to identify, register and review the diagnoses of incident cases of haematological malignancies (HM).

Participants

The whole child population aged 0–14 resident in Sardinia.

Primary and secondary outcome measures

Incidence and time trend of childhood HM and childhood acute lymphoblastic leukaemia (ALL) over the study period, and use of Bayesian methods to plot the probability of areas with excess incidence on the regional map.

Results

Overall, 675 HM cases, including 378 ALL cases, occurred among children aged 0–14 years resident in Sardinia in 1974–2003, with an incidence rate of 6.97x10-5 (95% CI 6.47 to 7.51) and 3.85x10-5 (95% CI 3.48 to 4.26), respectively. Incidence of HM and ALL showed an upward trend along the study period especially among females. Three communes out of the 356 existing in 1974, namely Ittiri, Villa San Pietro and Carbonia, stand out as areas with excess incidence of HM and ALL in particular and another, Carloforte, for ALL only.

Conclusions

Our results might serve as convincing arguments for extending the coverage of routine cancer registration over the whole Sardinian population, while prompting further research on the genetic and environmental determinants in the areas at risk.

View on the web

Tranexamic ACid during PancereaticoDuodenectomy (TAC-PD)

alkiviadis.1961 shared this article with you from Inoreader

bmjopen-default-cover.png

Introduction

Pancreaticoduodenectomy (PD) is a major gastroenterological surgery that results in a substantial amount of blood loss. Several studies have demonstrated that major blood loss during PD is associated with both short-term and long-term poor outcomes. Administration of perioperative tranexamic acid (TXA) has been reported to reduce intraoperative blood loss in various surgeries, including cardiovascular surgery and orthopaedic surgery. Nevertheless, the effect of perioperative TXA use in patients undergoing PD has not been investigated. This study aims to investigate the effect of TXA on blood loss during PD.

Methods and analysis

A multicentre (six hospitals), randomised, blind (patient-blinded, surgeon-blinded, anaesthesiologist-blinded, monitor-blinded), placebo-controlled trial of TXA during PD was started in September 2019. Patients undergoing PD for biliary, duodenal or pancreatic diseases are randomly assigned to the TXA or placebo group. The stratification factors are the institutions and preoperative clinical diagnosis. Before skin incision, the participants in TXA group are administrated 1 g TXA as a loading infusion followed by a maintenance infusion of 125 mg/hour TXA until the end of surgery or 8 hours from the incision. Participants in the placebo group are administrated the same volume of saline that is indistinguishable from the TXA. The primary outcome is blood loss during PD. The secondary outcomes are intraoperative and postoperative (up to day 2) blood transfusions, operation time, anaesthesia time, postoperative laboratory variables, length of hospital stay, in-hospital and 90-day morta lity and postoperative complications occurring within 28 days of surgery or requiring readmission. To date, 115 patients of a planned 220 have been enrolled in the study.

Ethics and dissemination

This protocol was approved by the Nagoya University Clinical Research Review Board and is registered with Japan Registry of Clinical Trials on 15 August 2019. The results of this trial will be disseminated through peer-reviewed journals.

Trial registration number

jRCTs041190062.

View on the web

Impact of SARS-CoV-2 (COVID-19) on pregnancy

alkiviadis.1961 shared this article with you from Inoreader

bmjopen-default-cover.png

Introduction

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been growing at an accelerating rate, and has become a public health emergency. Pregnant women and their fetuses are susceptible to viral infection, and outcomes in this population need to be investigated.

Methods and analysis

PubMed, Web of Science, Embase, CINAHAL, Latin American and Caribbean Health Sciences Literature, clinicaltrials.gov, SCOPUS, Google Scholar and Cochrane Central Controlled Trials Registry will be searched for observational studies (cohort and control cases) published from December 2019 to present. This systematic review and meta-analysis will include studies of pregnant women at any gestational stage diagnosed with COVID-19. The primary outcomes will be maternal and foetal morbidity and mortality. Three independent reviewers will select the studies and extract data from the original publications. The risk of bias will be assessed using the Newcastle-Ottawa Scale for observational studies. To evaluate the strength of evidence from the included data, we will use Grading of Recommendation Assessment, Development, and Evaluation method. Data synthesis will be performed using Review Manager software V.5.2.3. To assess heterogeneity, we will compute the I2 statistics. Additi onally, a quantitative synthesis will be performed if the included studies are sufficiently homogenous.

Ethics and dissemination

This study will be a review of the published data, and thus it is not necessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal.

PROSPERO registration number

PROSPERO 2020: CRD42020181519.

View on the web

End-stage renal disease as a risk factor for epiglottitis

alkiviadis.1961 shared this article with you from Inoreader

bmjopen-default-cover.png

Objectives

Patients with uremia are prone to infection; however, end-stage renal disease (ESRD) as a risk factor for acute epiglottitis warrants study. We investigated the risk of severe epiglottitis requiring hospitalisation in patients with ESRD.

Setting

We conducted a retrospective matched cohort study by using the claims data of Taiwan's National Health Insurance Research Database.

Participants

We identified an ESRD cohort with 87 908 patients newly diagnosed in 2000–2013 and underwent dialysis. The non-ESRD cohort comprised patients who had not received a diagnosis of ESRD, and they were matches to the ESRD cohort (1:1) by sex, age, residence urbanisation level, monthly income, and diabetes and hypertension status.

Primary and secondary outcome measures

The cumulative incidence of epiglottitis at the end of 2013 was analysed with Kaplan-Meier methods and log-rank tests. The HR of epiglottitis was calculated using the Cox proportional hazards model after adjustment for confounding factors.

Results

The overall epiglottitis incidence rate was 94% greater in the ESRD cohort than in the non-ESRD cohort (10.3 vs 5.3 cases per 100 000 person-years, p=0.002), with an adjusted HR of 1.89 (95% CI: 1.23 to 2.91, p=0.004). In the log-rank analysis, compared with the non-ESRD group, the epiglottitis cumulative incidence was significantly higher in the ESRD group (p=0.003). Epiglottitis did not exhibit an association with higher rates of airway interventions, intensive care unit admissions or longer hospitalisation in patients with ESRD than in controls.

Conclusions

This nationwide matched cohort study indicated that ESRD patients should be monitored for the risk of severe epiglottitis requiring hospitalisation.

View on the web

Δευτέρα 2 Νοεμβρίου 2020

Neutrophil extracellular trap components and myocardial recovery in post-ischemic acute heart failure

als.fakia shared this article with you from Inoreader

journal.pone.0241333.g003&size=inline

by Miriam Sjåstad Langseth, Geir Øystein Andersen, Trygve Husebye, Harald Arnesen, Manuela Zucknick, Svein Solheim, Jan Eritsland, Ingebjørg Seljeflot, Trine Baur Opstad, Ragnhild Helseth

Objective

The role of neutrophil extracellular traps (NETs) in acute heart failure is unknown. We recently showed that interleukin 8, a putative NETs stimulator, was associated with myocardial recovery in acute heart failure complicating ST-elevation myocardial infarction (STEMI). In this exploratory post-hoc study, we aimed to investigate the role of NETs components in relation to myocardial function and interleukin 8 in STEMI patients with symptomatic acute heart failure.

Methods

In 61 STEMI patients developing acute heart failure within 48 hours of successful revascularization, wall motion score index (WMSI), global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF) were assessed by echocardiography at baseline and on day 5. Blood drawn at baseline and days 1, 2 and 5 was used to quantify double-stranded DNA (dsDNA), myeloperoxidase-DNA complexes (MPO-DNA) and citrullinated histone 3 (CitH3). The area under the curve (AUC) of each NETs marker and int erleukin 8 was approximated for the first 5 days.

Results

dsDNAAUC and MPO-DNAAUC correlated significantly with change in WMSI from baseline to day 5 (rs = 0.28 for both, p≤0.05), whereas NETs AUCs did not correlate with changes in GLS and LVEF. dsDNAAUC was significantly correlated with interleukin 8AUC (r = 0.40, p = 0.003). However, mixed model regression could not identify a significant effect of the NETs components on myocardial function parameters.

Conclusions

In this cohort with acute heart failure complicating STEMI, NETs components were partly correlated with myocardial function and interleukin 8 levels, yet no causal relationship between NETs components and myocardial recovery could be established.

Clinical trial registration

ClinicalTrials.gov, identifier: NCT00324766.

View on the web

Image-guided percutaneous sclerotherapy of venous malformations of the head and neck: Clinical and MR-based volumetric mid-term outcome

als.fakia shared this article with you from Inoreader

journal.pone.0241347.g003&size=inline

by Dominik F. Vollherbst, Philipp Gebhart, Steffen Kargus, Astrid Burger, Reinald Kühle, Patrick Günther, Jürgen Hoffmann, Martin Bendszus, Markus A. Möhlenbruch

Objective

To report the clinical and MRI-based volumetric mid-term outcome after image guided percutaneous sclerotherapy (PS) of venous malformations (VM) of the head and neck.

Methods

A retrospective analysis of a prospectively maintained database was performed, including patients with VM of the head and neck who were treated with PS. Only patients with available pre- and post-interventional MRI were included into this study. Clinical outcome, which was subjectively assessed by the patients, their parents (for paediatric patients) and/or the physicians, was categorized as worse, unchanged, minor or major improvement. Radiological outcome, determined by MRI-based volumetric measurements, was categorized as worse (>10% increase), unchanged (≤10% increase to Results

Twenty-seven patients were treated in 51 treatment sessions. After a mean follow-up of 31 months, clinical outcome was worse for 7.4%, unchanged for 3.7% of the patients, while there was minor and maj or improvement for 7.4% and 81.5%, respectively. In the volumetric imaging analysis 7.4% of the VMs were worse and 14.8% were unchanged. Minor improvement was observed in 22.2%, intermediate improvement in 44.4% and major improvement in 11.1%. The rate of permanent complications was 3.7%.

Conclusion

PS can be an effective therapy to treat the symptoms of patients with VMs of the head and neck and to downsize the VMs. MRI-based volumetry can be used to objectively follow the change in size of the VMs after PS. Relief of symptoms frequently does not require substantial volume reduction.

View on the web

Consideration of body mass index (BMI) in the association between hand grip strength and hypertension: Korean Longitudinal Study of Ageing (KLoSA)

als.fakia shared this article with you from Inoreader

journal.pone.0241360.t003&size=inline

by Doukyoung Chon, Jaeyong Shin, Jae-Hyun Kim

Objective

The purpose of this study was to investigate the association between grip strength and hypertension in the Korean population aged 65 years or older. Furthermore, individual differences in BMI were taken into account to examine whether grip strength or a relative grip strength predicted hypertension better.

Methods

Data from the Korean Longitudinal Study of Ageing from 2006 to 2016 were assessed, and a total of 3,383 participants were analyzed in our study (Male: 1,527, Female: 1,856). Using the generalized estimating equation model, the association between grip strength and hypertension, assessed by the response to the question 'have you ever been diagnosed with hypertension from your doctor?', over the follow-up period was analyzed. The relative grip strength, calculated by dividing the mean grip strength by BMI, was also analyzed in association of hypertension.

Results

Both grip strength and relative grip strength were significantly associated with hy pertension in our sample. However, the results were more significant in the total sample when relative grip strength was used. In terms of grip strength, as the High group as reference: Low (Odds Ratio (OR): 1.238, 95% Confidence Interval (CI): 1.096, 1.397), Middle Low (OR: 1.104, 95% CI: 0.990, 1.231), and Middle high (OR: 1.024, 95% CI: 0.934, 1.122). In the analysis using relative grip strength, as High group as reference: Low (OR: 1.393, 95% CI: 1.234, 1.573), Middle low (OR: 1.232, 95% CI: 1.104, 1.374), and Middle high (OR:1.104, 95% CI: 1.009, 1.209). Furthermore, the lower QIC measure in the model with relative grip strength (QIC: 25,251) compared with the one using grip strength (QIC: 25,266) indicated a better model fit in the former.

Conclusions

The results of the current study strengthen the previous findings in regards to hand grip strength and health. Furthermore, the results of our study shines light on the necessity of considering individual differences in BM I, when using a physical measure as a study variable.

View on the web

Metabolomics profiles associated with diabetic retinopathy in type 2 diabetes patients

als.fakia shared this article with you from Inoreader

journal.pone.0241365.g002&size=inline

by Jun Ho Yun, Jeong-Min Kim, Hyun Jeong Jeon, Taekeun Oh, Hyung Jin Choi, Bong-Jo Kim

Diabetic retinopathy (DR) is a common complication of diabetes, and it is the consequence of microvascular retinal changes due to high glucose levels over a long time. Metabolomics profiling is a rapidly evolving method used to identify the metabolites in biological fluids and investigate disease progression. In this study, we used a targeted metabolomics approach to quantify the serum metabolites in type 2 diabetes (T2D) patients. Diabetes patients were divided into three groups based on the status of their complications: non-DR (NDR, n = 143), non-proliferative DR (NPDR, n = 123), and proliferative DR (PDR, n = 51) groups. Multiple logistic regression analysis and multiple testing corrections were performed to identify the significant differences in the metabolomics profiles of the different analysis groups. The concentrations of 62 metabolites of the NDR versus DR group, 53 metabolites of the NDR versus NPDR group, and 30 metabolites of the NDR versus PDR group were found to be si gnificantly different. Finally, sixteen metabolites were selected as specific metabolites common to NPDR and PDR. Among them, three metabolites including total DMA, tryptophan, and kynurenine were potential makers of DR progression in T2D patients. Additionally, several metabolites such as carnitines, several amino acids, and phosphatidylcholines also showed a marker potential. The metabolite signatures identified in this study will provide insight into the mechanisms underlying DR development and progression in T2D patients in future studies.
View on the web

Αναζήτηση αυτού του ιστολογίου